LX2020
LX2020-01
Phase 2 gene_therapy active
Quick answer
LX2020 for Arrhythmogenic Cardiomyopathy is a Phase 2 program (gene_therapy) at Lexeo Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lexeo Therapeutics
- Indication
- Arrhythmogenic Cardiomyopathy
- Phase
- Phase 2
- Modality
- gene_therapy
- Status
- active